Month: March 2022

Harboes Bryggeri A/S – Trading Report for Q3 2021/2022 In this connection, CEO Søren Malling states: “We are pleased that in a challenging quarter in terms of sales, we can continue to realize revenue that is growing compared to the previous year. It is the result of a targeted effort to navigate as best as possible in a market situation where both bottlenecks in the supply chains an d the competitive situation in general affect the potential. With a markedly increasing effect from Q3, the higher energy, raw material and packaging prices have taken hold, and this affect earnings in the quarter, which are unsatisfactory. We are fully focused on acting as efficiently as possible under the given market conditions, including through close dialogue with customers get implementation of the necessary price increases to meet the general...

Record Fourth Quarter Net Revenue of $77.4 million, up 43.4% versus Prior Year Fiscal Year 2022 Outlook includes 30% Net Revenue Growth AUSTIN, Texas, March 10, 2022 (GLOBE NEWSWIRE) — Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today reported financial results for its fourth quarter and fiscal year ended December 26, 2021. Financial highlights for the fourth quarter and fiscal year 2021 include:Fourth Quarter 2021 Net Revenue increase of 43.4% to a record $77.4 million Fiscal Year 2021 Net Revenue increase of 21.8% to $260.9 million Fiscal Year 2021 Net Income of $2.4 million Fiscal Year 2021 Adjusted EBITDA of $8.0 million1“2021 was a great year for Vital Farms’ top-line growth, and I want to thank our stakeholders, including our crew members, farmers,...

Ready to launch BXCL501 upon approval as Company nears April 5, 2022 PDUFA action date Initiated TRANQUILITY II AND III pivotal Phase 3 trials for BXCL501 in acute treatment of agitation associated with Alzheimer’s disease Submitted IND to evaluate BXCL501 as adjunctive treatment for major depressive disorder (MDD) Demonstrated encouraging composite response rates for BXCL701 in combination with KEYTRUDA® for mCRPC in SCNC and adenocarcinoma cohorts To host conference call today, March 10, 2022, at 8:30 a.m. ET NEW HAVEN, Conn., March 10, 2022 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the fourth quarter and...

Lead Product Candidate, IMM-1-104, displays broad activity against a wide range of animal tumor models driven by MAPK pathway activating mutations including KRAS-G12D, KRAS-G12S, KRAS-G12C, NRAS-Q61R, and BRAF-V600E; IND filing is expected in Q3 2022 IMM-6-415, designed to sensitize otherwise-resistant tumors to select immunotherapies, moves into IND-enabling studies Cash, cash equivalents and marketable securities of $150.2M is expected to provide cash runway into Q3 2024 CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today reported financial results for the fourth quarter and full year ended December...

BEIJING, March 10, 2022 (GLOBE NEWSWIRE) — Chindata Group Holdings Limited (“Chindata Group” or the “Company”) (Nasdaq: CD), a leading carrier-neutral hyperscale data center solution provider in Asia-Pacific emerging markets, today announced its unaudited financial results for the fourth quarter and full year 2021. To supplement the Company’s consolidated financial results presented in accordance with U.S. GAAP, Chindata Group uses adjusted EBITDA, adjusted EBITDA margin, adjusted net income and adjusted net income margin as non-GAAP financial measures, which are described further below. Recent Financial and Operating HighlightsNew senior management team announced and solid leadership in place. The Company announced new senior management team in late February and early March. New and experienced leadership are in place and in...

VANCOUVER, British Columbia, March 10, 2022 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) is pleased to announce its financial and operating results for the year ended December 31, 2021. All dollar amounts are in US dollars (US$). “2021 marked another strong year for Endeavour Silver. Our two producing mines – Guanaceví and Bolañitos – generated significant operating cash flow that we are using to extend mine lives and fund future growth,” stated Dan Dickson, CEO of Endeavour Silver. “Investment in the next leg of our growth, the transformational Terronera project, began last fall and is advancing well. While project financing is moving more slowly than expected, the project continues to move forward and with the receipt of financing and board approval in the next couple of months,...

Completed Initial Public Offering, Raising Gross Proceeds of $25.0 Million Expedited Clinical Program for CTx-1301 Expected to Reduce Capital Requirements and Time to Approval KANSAS CITY, Kan., March 10, 2022 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three and 12 months ended December 31, 2021, and provided a clinical and business update. “Our recent initial public offering was a significant milestone for Cingulate in advancing our mission to help Attention Deficit/Hyperactivity Disorder (ADHD) patients overcome their significant unmet needs in using currently available...

Full Year Net Sales increase 9.4% to $698.6 million Full Year diluted EPS of $0.90 increase 117% compared to 2020 and 55% compared to 2019 Full year positive free cash flow of $81.6 million1 Fourth quarter Net Sales increase 5.8% to $270.8 million; diluted EPS of $0.53 MOUNT HOREB, Wis., March 10, 2022 (GLOBE NEWSWIRE) — Duluth Holdings Inc. (dba, Duluth Trading Company) (“Duluth Trading” or the “Company”) (NASDAQ: DLTH), a growing lifestyle brand of men’s and women’s casual wear, workwear and accessories, today announced its financial results for the fiscal fourth quarter and fiscal year ended January 30, 2022. Highlights for the Fourth Quarter Ended January 30, 2022Net sales increased 5.8% to $270.8 million compared to $256.0 million in the prior-year fourth quarter Gross margin increased to 53.8% compared to 53.0% in the...